Biotech Business - October 4, 2024
Xbrane provides update from Scientific Advice with US FDA on Xdivane
Xbrane Biopharma has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo biosimilar candidate Xdivane.
Biotech Business - September 27, 2024
Evaxion expands vaccine development collaboration
Evaxion Biotech has entered into an option and license agreement with MSD for two preclinical vaccine candidates.
Biotech Business - September 24, 2024
QureTech Bio secures major investment
The company has received a substantial investment from Kempestiftelserna.
Biotech Business - September 17, 2024
Oncopeptides signs license agreement with SCBIO
Oncopeptides has announced that it has signed an exclusive license and supply agreement with SCBIO, a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea.
Biotech Business - September 6, 2024
Pila Pharma raises capital for international obesity study
The company has recently raised SEK 10 million in directed issue for a novel obesity-related study. The aim is to study drug tolerance and the effects of the company’s molecule on obesity. The Phase-2a-study will be conducted over the next year and the capital raised will support the study with the objective to assess the […]
Biotech Business - September 5, 2024
IRLAB is granted additional patent for drug candidate
IRLAB Therapeutics has announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project. “The […]